Effect of Lansoprazole on Human Leukocyte Function

Abstract

Recent findings on the capacity of omeprazole to influence various leukocyte functions, in vitro, raises the question on the potential use of protonic pump inhibitors, commonly used in the treatment of acid-secretion-related disorders, as immunomodulators. The aim of this study was to evaluate the in vitro effect of lansoprazole on human natural killer (NK) cell cytotoxix activity, chemotaxis and superoxide anion (O2*-) generation exerted by polymorphonucleated cells (PMNs). NK cytotoxicity activity was assessed by a 51Cr release assay, PMN chemotaxis was determined by an under agarose method and O2*- generation was analyzed on the basis of reduced cytochrome C. Incubation times with lansoprazole was 30 min for PMNs and 1-4.5 hours for NK cells, respectively. Lansoprazole induced significant dose dependent inhibition of NK cell activity and PMN functions at concentrations ranging from 100 to 1,000 microM. This study demonstrate that lansoprazole, like omeprazole, inhibits several leukocyte functions, in vitro, then suggesting that protonic pump inhibitors are able to provoke these effects, at least at certain doses.

Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study

“…10 This may, in turn, predispose to microaspiration of bacterial gastrointestinal contents and pneumonia. Furthermore, evidence shows that proton pump inhibitors impair immune cell function, [31][32][33][34] which is another potential mechanism to explain the differential risk that we observed.…”

Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis

“…52 Third, in vitro studies have shown that acid-suppressive drugs may impair the function of neutrophils and the activity of natural killer cells. [53][54][55][56][57][58][59] Interestingly, the most striking increase in the risk of pneumonia in association with proton pump inhibitors was observed in the first week of use. The risk of pneumonia in association with use of proton pump inhibitors was attenuated, but still significant, between 30 and 180 days.…”

Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

“…The Gulmez study [45] also identified a temporal relationship between PPI treatment and pneumonia. The highest incidence of pneumonia was associated with PPI administration within seven days of diagnosis, with an odds ratio of 5.0 (95% CI: 2.1-11.7).…”

“…The humoral defense mechanism against bacterial colonization is mediated by the white blood cells. In vitro studies [43][44][45] have assessed the cytotoxicity of natural killer (NK) cells when exposed to target cells in varying ratios and in different solution media. Not surprisingly, as the ratio of NK cells to target cells increased, the percentage of target cells lysed increased, suggesting a positive correlation.…”